Financial reports
10-Q
2012 Q2
Quarterly report
26 Jul 12
10-Q
2012 Q1
Quarterly report
26 Apr 12
10-K
2011 FY
Annual report
28 Feb 12
10-Q
2011 Q3
Quarterly report
28 Oct 11
10-Q
2011 Q2
Quarterly report
28 Jul 11
10-Q
2011 Q1
Quarterly report
29 Apr 11
10-K
2010 FY
Annual report
24 Feb 11
10-Q
2010 Q3
Quarterly report
27 Oct 10
10-Q
2010 Q2
Quarterly report
22 Jul 10
10-Q
2010 Q1
Quarterly report
29 Apr 10
Current reports
8-K
Completion of Acquisition or Disposition of Assets
8 Aug 12
8-K
Entry into a Material Definitive Agreement
1 Aug 12
8-K
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
16 Jul 12
8-K
Human Genome Sciences Announces Adoption of
17 May 12
8-K
Submission of Matters to a Vote of Security Holders
16 May 12
8-K
Results of Operations and Financial Condition
24 Apr 12
8-K
Human Genome Sciences Announces Unsolicited Offer from Glaxosmithkline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives
19 Apr 12
8-K
Results of Operations and Financial Condition
27 Feb 12
8-K
Human Genome Sciences Reports Progress with Commercialization of Benlysta® and Announces 2012 Goals at Jpmorgan Healthcare Conference
9 Jan 12
8-K
GSK receives initial data from the first completed phase III study of albiglutide in type 2 diabetes
16 Nov 11
Registration and prospectus
15-12B
Securities registration termination
13 Aug 12
POS AM
Prospectus update (post-effective amendment)
9 Aug 12
POSASR
Automatic shelf registration (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
Proxies
DEFA14A
Additional proxy soliciting materials
30 Mar 12
DEF 14A
Definitive proxy
30 Mar 12
DEFA14A
Additional proxy soliciting materials
27 Apr 11
DEFA14A
Additional proxy soliciting materials
30 Mar 11
DEF 14A
Definitive proxy
30 Mar 11
DEF 14A
Definitive proxy
7 Apr 10
DEFR14A
Revised proxy
31 Mar 09
DEF 14A
Definitive proxy
24 Mar 09
DEF 14A
Definitive proxy
25 Mar 08
PRE 14A
Preliminary proxy
14 Mar 08
Other
EFFECT
Notice of effectiveness
10 Aug 12
CT ORDER
Confidential treatment order
9 Aug 12
CT ORDER
Confidential treatment order
9 Aug 12
CORRESP
Correspondence with SEC
26 Jul 12
UPLOAD
Letter from SEC
26 Jul 12
UPLOAD
Letter from SEC
26 Jul 12
CORRESP
Correspondence with SEC
23 Jul 12
CT ORDER
Confidential treatment order
17 Jul 12
CT ORDER
Confidential treatment order
17 Jul 12
CORRESP
Correspondence with SEC
13 Jun 12
Ownership
SC 13D/A
GAMCO INVESTORS, INC. ET AL
31 Jul 12
SC 13D
GAMCO INVESTORS, INC. ET AL
20 Jul 12
11-K
Annual report of employee stock purchases
28 Mar 12
11-K
Annual report of employee stock purchases
31 Mar 11
11-K
Annual report of employee stock purchases
29 Mar 10
11-K
Annual report of employee stock purchases
30 Mar 09
11-K
Annual report of employee stock purchases
31 Mar 08
11-K
Annual report of employee stock purchases
29 Mar 07
11-K
Annual report of employee stock purchases
30 Mar 06
11-K
Annual report of employee stock purchases
29 Mar 05